BIOGEN INC. — Director's Dealing 2020

Feb 14, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOGEN INC. (BIIB)
CIK: 0000875045
Period of Report: 2020-02-12

Reporting Person: Vounatsos Michel (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-02-12	Common Stock	M	6234	—	Acquired	28063.321	Direct
2020-02-12	Common Stock	F	2340	$331.76	Disposed	25723.321	Direct
2020-02-12	Common Stock	M	5760	—	Acquired	31483.321	Direct
2020-02-12	Common Stock	F	2555	$331.76	Disposed	28928.321	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-02-12	Restricted Stock Unit	$0	M	6234	Disposed	2021-02-12	Common Stock (6234)	Direct
2020-02-12	Restricted Stock Unit	$0	J	5870	Disposed	2021-02-12	Common Stock (5870)	Direct
2020-02-12	Restricted Stock Unit	$0	M	5760	Disposed	2022-02-12	Common Stock (5760)	Direct
2020-02-12	Restricted Stock Unit	$0	J	6762	Disposed	2022-02-12	Common Stock (6762)	Direct
2020-02-12	Restricted Stock Unit	$0	A	37680	Acquired	2023-02-12	Common Stock (37680)	Direct

Footnotes

F1: The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price following and including the grant date]).

F2: This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.